Palosuran, with the CAS number 540769-28-6, is a chemical compound that functions primarily as a selective antagonist of the endothelin receptor. It is characterized by its ability to inhibit the action of endothelin, a potent vasoconstrictor peptide involved in various physiological processes, including blood pressure regulation and vascular tone. Palosuran is notable for its potential therapeutic applications in treating conditions such as hypertension and heart failure, where modulation of the endothelin pathway may provide beneficial effects. The compound typically exhibits a favorable pharmacokinetic profile, allowing for effective oral bioavailability. Its chemical structure includes specific functional groups that contribute to its receptor selectivity and binding affinity. As with many pharmacological agents, the safety and efficacy of Palosuran are evaluated through clinical trials, and its use is subject to regulatory approval. Overall, Palosuran represents a significant interest in cardiovascular pharmacotherapy, reflecting ongoing research into endothelin receptor antagonism.

Palosuran

540769-28-6: ACT 058362, 1-[2-(4-Benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(2-methylquinolin-4-yl)urea, Urea, N-[2-[4-hydroxy-4-(phenylmethyl)-1-piperidinyl]ethyl]-N′-(2-methyl-4-quinolinyl)-, Palosuran, N-[2-[4-Hydroxy-4-(phenylmethyl)-1-piperidinyl]ethyl]-N′-(2-methyl-4-quinolinyl)urea

Palosuran is a cyclic peptide polymerase chain that has been shown to inhibit the growth of cancer cells in humans. Palosuran binds to urotensin II, which is an endogenous vasopressin-like peptide with vasoconstrictor and antidiuretic effects. Palosuran inhibits the binding of urotensin II to its receptor, reducing blood flow and fluid retention. It also reduces the production of growth factor-β1 and cytosolic Ca2+, which are important for cell proliferation. Palosuran has been shown to be effective as a monotherapy or in combination therapy with other drugs used in cancer treatment (e.g., doxorubicin).

Palosuran (ACT-058362) (ACT-058362) is a new potent and specific antagonist of the human UT receptor.

CAS 540769-28-6: Palosuran

Palosuran

Ref: 3D-QWA76928

Palosuran

Ref: 54-BUP09870

Palosuran

Ref: TM-T2058